Clinical Trial

Trial Protocol ID USOR 23133_D361DC00001_CAPItello-292

Trial Description

A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Carol Tweed, MD

Disease Types

Sponsor

  • AstraZeneca

ClinicalTrials.gov NCT ID

  • NCT04862663